Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Successful Phase 3 Trial for Belatacept

May 3, 2010 6:26 am | News | Comments

Two-year results from phase 3 clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.

TOPICS:

Study Implicates Rewired Interactions In Cancer

May 3, 2010 6:07 am | News | Comments

Genes interact in complex networks that govern cellular processes, much like people connect a social network through relationships.

TOPICS:

New Tool Enables Wider Analysis Of Deep Sequencing

May 3, 2010 6:04 am | News | Comments

Scientists seeking to understand the machinations of the proteins behind genetics have a powerful new tool at their disposal, courtesy of researchers at the Stanford University School of Medicine.

TOPICS:
Advertisement

Pitt Researchers Explain Omega-3 Abilities

May 3, 2010 5:57 am | News | Comments

Scientists at the University of Pittsburgh School of Medicine have located a group of new mediators that not only can explain how omega-3 fatty acids reduce inflammation, but also hint at novel treatments for a host of diseases linked to inflammatory processes.

TOPICS:

McNeil Issues Children's Medicine Recall

May 3, 2010 5:49 am | News | Comments

The Food and Drug Administration is investigating a health-care company for possible other problems following its recall of more than 40 over-the-counter infant's and children's liquid medications.

TOPICS:

FDA Approves Breakthrough Cancer Therapy Provenge

April 30, 2010 10:30 am | by Matthew Perrone, AP Business Writer | News | Comments

Dendreon Corp.'s Provenge, a first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval, offering an important alternative to more taxing treatments like chemotherapy.

TOPICS:

Simulation Software

April 30, 2010 7:08 am | Product Releases | Comments

The time-consuming scientific research behind drug discovery can now be accelerated with the launch of AMBER 11, a software tool that enables bio-scientists to harness the power of supercomputing on their desktop PC.

TOPICS:

Biomarker Panel

April 30, 2010 6:46 am | Product Releases | Comments

Beckman Coulter, Inc. introduces Solastra, a comprehensive CE-marked panel of conjugated-antibody cocktails for the characterization of hematolymphoid neoplasia by flow cytometry.

TOPICS:
Advertisement

Commentary: Will Provenge Be New Standard of Care?

April 30, 2010 6:36 am | by Fleur Pijpers, Senior Analyst, Datamonitor | News | Comments

Despite FDA approval, it remains to be seen how frequently Provenge will be used in castration-resistant prostate cancer (CRPC), according to a Datamonitor analyst.

TOPICS:

CEVEC and Aragen Sign Strategic License Agreement

April 30, 2010 6:29 am | News | Comments

CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc., a California-based contract research and development organization, have signed of a strategic license agreement.

TOPICS:

Mallinckrodt Baker Signs Deal With VWR International

April 30, 2010 6:17 am | News | Comments

Covidien announced that its Mallinckrodt Baker business unit has entered into a multi-year agreement with global laboratory supply company, VWR International, LLC, to distribute Mallinckrodt Baker’s J.T.Baker brand products in Eastern and Central Europe.

TOPICS:

All Immunosuppressive Drugs Carry Same Cancer Risk

April 30, 2010 6:11 am | News | Comments

Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

TOPICS:

University Finds MS Biomarkers A Decade Before Symptoms

April 30, 2010 6:07 am | News | Comments

Multiple sclerosis (MS) is an equal opportunity destroyer. It attacks the central nervous system and eventually renders most patients disabled.

TOPICS:

FDA Approves Once-Daily Kaletra

April 30, 2010 5:56 am | News | Comments

Abbott announced that the U.S. Food and Drug Administration approved once-daily dosing of Kaletra for adult patients with HIV who have previously taken antiretroviral therapy.

TOPICS:

Provenge Vaccine Receives FDA Approval

April 30, 2010 5:45 am | by Matthew Perrone | News | Comments

A first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval, offering an important alternative to more taxing treatments like chemotherapy.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading